Viktor Adalsteinsson

Group Leader

Broad Institute
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Liquid biopsies can enable cancer detection and monitoring yet remain limited by low concentrations of ctDNA. To address this limitation, we previously introduced a monoclonal antibody (mAb) “priming agent” that transiently increased the concentration of ctDNA in blood. Here, we investigated the molecular features that drive this effect. In a panel of novel mAbs that bound cfDNA, both those targeting dsDNA and those targeting mononucleosomes increased the concentration of ctDNA. mAbs with high avidity to dsDNA performed best, suggesting dsDNA as the key binding target. One agent preserved short, biologically informative molecules of cfDNA typically depleted at baseline. The Fc domain was dispensable, as F(ab’)2 fragments retained priming activity. Leveraging these insights, we engineered single-chain agents using the dsDNA binding domain sso7d, expanding priming strategies beyond immunoglobulins. This study identifies the molecular features and general design principles for mAb-based priming agents to enhance recovery and detection of ctDNA. Significance Low concentration of ctDNA limits the sensitivity of liquid biopsies in many applications. This study shows how engineered antibodies and other dsDNA-binding molecules can inhibit clearance of ctDNA from the bloodstream and increase concentration of ctDNA in a blood draw, and identifies the key features that enable this activity. Modulation of cfDNA in the bloodstream using these agents can increase recovery of ctDNA and improve the performance of liquid biopsies for cancer detection.

Year:

2026

Detecting somatic mutations in normal tissues is challenging due to sequencing errors and the low allele fractions of post-zygotic variants. Duplex sequencing greatly reduces errors and can detect mutations at any allele fraction, but systematic, cross-platform comparisons are lacking. We present a comprehensive benchmarking of six duplex sequencing technologies used by the SMaHT Network: CODEC, CompDuplex-seq, HiDEF-seq, NanoSeq, ppmSeq, and VISTA-seq. We evaluated their performance using cord blood DNA, a tumor-normal cell line mixture, and homogenates from six human tissues. Each method shows distinct profiles in genomic footprint, sensitivity, and cost. Despite differences in library construction and sequencing platforms, estimates of mutation rates and mutational signatures are highly concordant. Integration with ultra-deep whole-genome sequencing shows that duplex approaches sensitively capture mutations and signatures beyond embryonic or clonally expanded variants. These results provide a foundation for selecting duplex methods and interpreting their data, enabling scalable single-molecule analyses of somatic mutation landscapes. Graphical Abstract

Year:

2025

Heatmap of MRD detection for both matched (on diagonal) and unmatched (off diagonal) tests using (A) the uniform background SNV frequency model and (B) the sample-specific background SNV frequency model. (C) Summary table of MRD + calls for both matched and unmatched tests using both background SNV frequency models. (D) Tumor fractions for MRD + tests and observed specificity for each patient-specific assay using the sample-specific background SNV frequency

Year:

2025

Purpose: Although ctDNA is a promising biomarker for minimal residual disease (MRD) detection in head and neck squamous cell carcinoma (HNSCC), more sensitive assays are needed for accurate MRD detection at clinically relevant time points. Ultrasensitive MRD detection early after surgery could guide adjuvant therapy decisions, but early ctDNA dynamics are poorly understood. Experimental Design: We applied minor allele–enriched sequencing through recognition oligonucleotides (MAESTRO), a whole-genome, tumor-informed, mutation enrichment sequencing assay, in a pooled testing format called MAESTRO-Pool, to plasma samples from patients with HNSCC collected shortly after surgery and during surveillance. We evaluated whether early MRD detection could predict outcomes. Results: Among 24 patients with predominantly human papillomavirus–independent (95.8%) HNSCC, rapid ctDNA clearance occurred by the first postoperative sample (1–3 days postoperatively) in nine patients without an event (recurrence or death). Thirteen of fifteen patients with an event were MRD-positive (positive predictive value = 92.9%; negative predictive value = 80%) with a median tumor fraction (TFx) of 54 parts per million (ppm; range 6–1,177 ppm). In the first and last samples of the early postoperative window, 8/13 and 10/13 patients, respectively, had TFx below 100 ppm, the detection limit of leading commercial assays. Early MRD detection correlated with worse overall survival (HR, 8.3; 95% confidence interval, 1.1–66.1; P = 0.02) and event-free survival (HR, 27.4; 95% confidence interval, 3.5–214.5; P Conclusions: Early postoperative MRD detection by MAESTRO was associated with recurrence and worse survival. Given the ultralow TFxs observed, ultrasensitive assays will be essential for reliable MRD detection during early postoperative time points to enable personalized adjuvant therapy decision-making in HNSCC. See related article by Bryan et al., p. 3483

Year:

2025

Purpose: The incidence of human papillomavirus (HPV)–associated head and neck squamous cell carcinoma (HPV + HNSCC) is increasing in the United States. Currently, there are no early detection approaches for HPV + HNSCC. Two blood-based analytes for early detection and diagnosis of HPV + HNSCC, circulating tumor HPV DNA (ctHPVDNA) and HPV early protein antibodies (HPV Ab), show promise, yet current approaches lack adequate diagnostic accuracy for broad clinical utility. Further, performance metrics across various assays for detecting these analytes alone or in combination have not been compared head-to-head. To address these limitations and knowledge gaps, we developed a multifeature HPV whole-genome sequencing (WGS) liquid biopsy for improved low-level ctHPVDNA detection. We defined the performance characteristics of this WGS-based approach and compared it head-to-head with existing blood-based HPV detection approaches to determine the optimal single or combinatorial biomarker strategy for a future prospective study of HPV + HNSCC early detection. Experimental Design: We tested blood samples from 304 participants: 152 patients with untreated incident HPV + HNSCC (77% stage I) and 152 general population control patients. We compared WGS-based ctHPVDNA detection, single-plex Droplet Digital PCR (ddPCR)–based ctHPVDNA detection, multiplex ddPCR-based ctHPVDNA detection, multiplex HPV Ab detection, and clinical standard-of-care tissue biopsy, benchmarked to gold-standard HPV + HNSCC tissue diagnosis. We then modeled the operational feasibility of these approaches as screening biomarkers for HPV + HNSCC. Results: HPV WGS sensitivity and specificity were 98.7% and 98.7%, respectively. Single-plex ddPCR sensitivity and specificity were 94.2% and 98.6%, respectively. Multiplex ddPCR sensitivity and specificity were 90.6% and 96.3%, respectively. HPV Ab sensitivity and specificity were 86.4% and 96.3%, respectively. A combinatorial approach using both HPV WGS and HPV Ab yielded a sensitivity and specificity of 87.4% and 98.8%, respectively. In a head-to-head comparison, HPV WGS demonstrated significantly improved diagnostic accuracy compared with ddPCR (Youden index for HPV WGS, 0.99 vs. ddPCR, 0.90; P P P Conclusions: HPV WGS–based ctHPVDNA detection demonstrated the highest sensitivity, specificity, and diagnostic accuracy and thus the lowest number needed to screen and highest positive predictive value compared with ddPCR-based ctHPVDNA detection, HPV Ab–based detection, and combinatorial approaches. These results highlight the promise of HPV WGS liquid biopsy for screening and early detection of HPV + HNSCC and the need for modeling and cost-effectiveness studies to evaluate and guide screening implementation. See related commentary by Haring et al., p. 3359 See related article by Sim et al., p. 3494

Year:

2025

Purpose While circulating tumor DNA (ctDNA) is a promising biomarker for minimal residual disease (MRD) detection in head and neck squamous cell carcinoma (HNSCC), more sensitive assays are needed for accurate MRD detection at clinically-relevant timepoints. Ultrasensitive MRD detection immediately after surgery could guide adjuvant therapy decisions, but early ctDNA dynamics are poorly understood. Experimental Design We applied MAESTRO, a whole-genome, tumor-informed, mutation-enrichment sequencing assay, in a pooled testing format called MAESTRO-Pool, to plasma samples from HNSCC patients collected immediately after surgery and during surveillance. We evaluated whether early MRD detection could predict outcomes. Results Among 24 predominantly HPV-independent (95.8%) HNSCC patients, rapid ctDNA clearance occurred by the first postoperative sample (1-3 days postoperatively) in 9 patients without an event (recurrence or death). 13/15 patients with an event were MRD+ (PPV = 92.9%; NPV = 80%) with a median tumor fraction (TFx) of 54 ppm (range 6-1,177 ppm). In the first and last sample of the immediate postoperative window, 8/13 and 10/13 patients had TFx below 100 ppm, respectively, the detection limit of leading commercial assays. Early MRD detection correlated with worse overall survival (HR = 8.3; 95% CI: 1.1-66.1; P = 0.02) and event-free survival (HR = 27.4; 95% CI: 3.5-214.5; P < 0.0001) independent of high-risk pathology. Conclusions Immediate postoperative MRD detection by MAESTRO was predictive of recurrence and death. Given the ultralow TFxs observed, ultrasensitive assays will be essential for reliable MRD detection during early postoperative timepoints to enable personalized adjuvant therapy decision-making in HNSCC.

Year:

2025

PURPOSE Somatic chromosomal alterations, particularly monosomy 3 and 8q gains, have been associated with metastatic risk in uveal melanoma (UM). Whole genome-scale evaluation of detectable alterations in cell-free DNA (cfDNA) in UM could provide valuable prognostic information. Our pilot study evaluates the correlation between genomic information using ultra-low-pass whole-genome sequencing (ULP-WGS) of cfDNA in UM and associated clinical outcomes. MATERIALS AND METHODS ULP-WGS of cfDNA was performed on 29 plasma samples from 16 patients, 14 metastatic UM (mUM) and two non-metastatic, including pre- and post-treatment mUM samples from 10 patients treated with immunotherapy and one with liver-directed therapy. We estimated tumor fraction (TFx) and detected copy-number alterations (CNAs) using ichorCNA. Presence of 8q amplification was further analyzed using the likelihood ratio test (LRT). RESULTS Eleven patients with mUM (17 samples) of 14 had detectable circulating tumor DNA (ctDNA). 8q gain was detected in all 17, whereas monosomy 3 was detectable in 10 of 17 samples. TFx generally correlated with disease status, showing an increase at the time of disease progression (PD). 8q gain detection sensitivity appeared greater with the LRT than with ichorCNA at lower TFxs. The only patient with mUM with partial response on treatment had a high pretreatment TFx and undetectable on-treatment ctDNA, correlating with her profound response and durable survival. CONCLUSION ctDNA can be detected in mUM using ULP-WGS, and the TFx correlates with DS. 8q gain was consistently detectable in mUM, in line with previous studies indicating 8q gains early in primary UM and higher amplification with PD. Our work suggests that detection of CNAs by ULP-WGS, particularly focusing on 8q gain, could be a valuable blood biomarker to monitor PD in UM.

Year:

2024

Collaborators (20)

Ross Merkin

Attending Physician, Medical Oncology, Center for Head and Neck Cancer

Massachusetts General Hospital

UNITED STATES
View details

Michael Lawrence

Assistant Professor

Broad Institute

UNITED STATES
View details

William Faquin

Professor of Pathology

Massachusetts General Hospital

UNITED STATES
View details

Gilad Evrony

NYU School of Medicine

UNITED STATES
View details

Sambit Kumar Mishra

Bioinformatics Scientist

Division of Cancer Epidemiology and Genetics, National Cancer Institute

UNITED STATES
View details

Guanlan Dong

Harvard University

UNITED STATES
View details

Adam Fisch

Assistant in Pathology

Massachusetts General Hospital

UNITED STATES
View details

Genevieve Boland

Chair of Surgery

Medical College of Wisconsin

UNITED STATES
View details

Shervin Tabrizi

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

G MAKRIGIORGOS

PROFESSOR

Dana-Farber Cancer Institute

UNITED STATES
View details

sangita choudhury

Assistant Professor

Boston Children's Hospital

UNITED STATES
View details

Ryan Sullivan

Harvard University

UNITED STATES
View details

Ruolin Liu

Broad Institute

UNITED STATES
View details

harshavardhan doddapaneni

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

Allen Feng

Assistant Professor

Harvard Medical School

UNITED STATES
View details

Tim Coorens

Research Group Leader

European Bioinformatics Institute

UNITED KINGDOM
View details

Mark Varvares

Professor and Chair

Massachusetts Eye and Ear

UNITED STATES
View details

Chenghang Zong

Baylor College of Medicine

UNITED STATES
View details

Peter Sadow

Director, Head & Neck Pathology

Harvard Medical School

UNITED STATES
View details

Christopher Walsh

Chief

Boston Children's Hospital

UNITED STATES
View details